Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?

Nature Clinical Practice Oncology volume 2, pages 20–21 (2005)Cite this article

boxed-textCunningham D et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Saltz L et al. (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract]. Proc Am Soc Clin Oncol, Abstract 7 and ASCO Virtual Meeting [http://www.ASCO.org/]

  2. Saltz LB et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201–1208

    Article  CAS  Google Scholar 

  3. Prewett MC et al. (2002) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8: 994–1003

    CAS  PubMed  Google Scholar 

  4. Schrag D (2004) The price tag on progress—chemotherapy for colorectal cancer. N Engl J Med 351: 317–319

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Attending Physician and Member, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Leonard B Saltz

Authors
  1. Leonard B Saltz
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Dr Saltz receives support from Imclone, Bristol Meyers Squibb, Pfizer, and Roche. He has served as a paid consultant for Pfizer, Roche, Sanofi, Genetech, and Taiho Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saltz, L. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?. Nat Rev Clin Oncol 2, 20–21 (2005). https://doi.org/10.1038/ncponc0057

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0057

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing